177 related articles for article (PubMed ID: 24048330)
1. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer--letter.
Radvanyi L; Pilon-Thomas S; Peng W; Sarnaik A; Mulé JJ; Weber J; Hwu P
Clin Cancer Res; 2013 Oct; 19(19):5541. PubMed ID: 24048330
[No Abstract] [Full Text] [Related]
2. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer--response.
Sznol M; Chen L
Clin Cancer Res; 2013 Oct; 19(19):5542. PubMed ID: 24048329
[No Abstract] [Full Text] [Related]
3. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer.
Sznol M; Chen L
Clin Cancer Res; 2013 Mar; 19(5):1021-34. PubMed ID: 23460533
[TBL] [Abstract][Full Text] [Related]
4. Identification of a hotspot on PD-L1 for pH-dependent binding by monoclonal antibodies for tumor therapy.
Liu H; Bi X; Zhou Y; Shi R; Yao S; Qi J; Feng H; Feng M; Yan J; Tan S
Signal Transduct Target Ther; 2020 Aug; 5(1):158. PubMed ID: 32839442
[No Abstract] [Full Text] [Related]
5. Could PD-1/PDL1 immune checkpoints be linked to HLA signature?
Correale P; Saladino RE; Nardone V; Giannicola R; Agostino R; Pirtoli L; Caraglia M; Botta C; Tagliaferri P
Immunotherapy; 2019 Dec; 11(18):1523-1526. PubMed ID: 31865873
[No Abstract] [Full Text] [Related]
6. PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade.
Hirsch L; Zitvogel L; Eggermont A; Marabelle A
Br J Cancer; 2019 Jan; 120(1):3-5. PubMed ID: 30413824
[TBL] [Abstract][Full Text] [Related]
7. PD-1/PD-L1 and immunotherapy for pancreatic cancer.
Feng M; Xiong G; Cao Z; Yang G; Zheng S; Song X; You L; Zheng L; Zhang T; Zhao Y
Cancer Lett; 2017 Oct; 407():57-65. PubMed ID: 28826722
[TBL] [Abstract][Full Text] [Related]
8. PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression.
Šmahel M
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28635644
[TBL] [Abstract][Full Text] [Related]
9. Comparison between PD-1/PD-L1 inhibitors (nivolumab, pembrolizumab, and atezolizumab) in pretreated NSCLC patients: Evidence from a Bayesian network model.
Wu Y; Lin L; Shen Y; Wu H
Int J Cancer; 2018 Dec; 143(11):3038-3040. PubMed ID: 29987914
[No Abstract] [Full Text] [Related]
10. The role of programmed cell death-1 (PD-1) and its ligands in pediatric cancer.
van Dam LS; de Zwart VM; Meyer-Wentrup FA
Pediatr Blood Cancer; 2015 Feb; 62(2):190-197. PubMed ID: 25327979
[TBL] [Abstract][Full Text] [Related]
11. Combinations take centre stage in PD1/PDL1 inhibitor clinical trials.
Upadhaya S; Neftelino ST; Hodge JP; Oliva C; Campbell JR; Yu JX
Nat Rev Drug Discov; 2021 Mar; 20(3):168-169. PubMed ID: 33177720
[No Abstract] [Full Text] [Related]
12. [Clinical Research Progress of Anti PD-1/PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer].
Huang Z; Li H; Fan Y
Zhongguo Fei Ai Za Zhi; 2015 Nov; 18(11):706-13. PubMed ID: 26582228
[TBL] [Abstract][Full Text] [Related]
13. Toxicities Associated With PD-1/PD-L1 Blockade.
Wang DY; Johnson DB; Davis EJ
Cancer J; 2018; 24(1):36-40. PubMed ID: 29360726
[TBL] [Abstract][Full Text] [Related]
14. Microbiota-Regulated Outcomes of Human Cancer Immunotherapy via the PD-1/PD-L1 Axis.
Patel J; Crawford JM
Biochemistry; 2018 Feb; 57(6):901-903. PubMed ID: 29350031
[No Abstract] [Full Text] [Related]
15. PD-1/PD-L1 blockade in cancer treatment: perspectives and issues.
Hamanishi J; Mandai M; Matsumura N; Abiko K; Baba T; Konishi I
Int J Clin Oncol; 2016 Jun; 21(3):462-73. PubMed ID: 26899259
[TBL] [Abstract][Full Text] [Related]
16. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
17. A decade of immune-checkpoint inhibitors in cancer therapy.
Robert C
Nat Commun; 2020 Jul; 11(1):3801. PubMed ID: 32732879
[TBL] [Abstract][Full Text] [Related]
18. From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway.
Zhan MM; Hu XQ; Liu XX; Ruan BF; Xu J; Liao C
Drug Discov Today; 2016 Jun; 21(6):1027-36. PubMed ID: 27094104
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibitors in lung cancer: an update.
Sullivan K; Preeshagul I; Budman D; Seetharamu N
Future Oncol; 2017 May; 13(11):955-959. PubMed ID: 28481150
[No Abstract] [Full Text] [Related]
20. Predictive Efficacy Biomarkers of Programmed Cell Death 1/Programmed Cell Death 1 Ligand Blockade Therapy.
Fang XN; Fu LW
Recent Pat Anticancer Drug Discov; 2016; 11(2):141-51. PubMed ID: 26916881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]